2024
Clinicopathologic features and prognosis of steatohepatitic hepatocellular carcinoma based on varying cutoffs of tumoral steatohepatitic changes
Zhang T, Niu N, Taddei T, Jain D, Zhang X. Clinicopathologic features and prognosis of steatohepatitic hepatocellular carcinoma based on varying cutoffs of tumoral steatohepatitic changes. American Journal Of Clinical Pathology 2024, aqae136. PMID: 39418121, DOI: 10.1093/ajcp/aqae136.Peer-Reviewed Original ResearchSH-HCCSteatohepatitic hepatocellular carcinomaHepatocellular carcinomaLiver diseaseHepatitis C virus infectionC virus infectionStage of fibrosisPresence of steatohepatitisOverall survivalHistological subtypesPrognostic factorsHCC subtypesBackground liverHCC casesClinicopathological featuresConventional HCCHistopathological patternsHyaline globulesTumor cellsMallory-Denk bodiesGlycogenated nucleiSteatotic liver diseaseHCCSurvival analysisSteatohepatitis
2022
Oral Cyanobacteria and Hepatocellular Carcinoma
Hernandez BY, Zhu X, Risch HA, Lu L, Ma X, Irwin ML, Lim JK, Taddei TH, Pawlish KS, Stroup AM, Brown R, Wang Z, Wong LL, Yu H. Oral Cyanobacteria and Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2022, 31: 221-229. PMID: 34697061, PMCID: PMC8755591, DOI: 10.1158/1055-9965.epi-21-0804.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis C virusHepatocellular carcinomaRisk factorsLiver diseaseHCC casesOral microbiomeU.S. case-control studyIndependent risk factorChronic liver diseaseFatty liver diseaseHCC risk factorsGut microbial alterationsType 2 diabetesCase-control studyLiver cancer developmentNSAID useAspirin useC virusB virusHCC riskNegative historyOral samplesSignificant associationCancer development
2021
Genetic susceptibility to hepatocellular carcinoma in chromosome 22q13.31, findings of a genome‐wide association study
Wang Z, Budhu AS, Shen Y, Wong LL, Hernandez BY, Tiirikainen M, Ma X, Irwin ML, Lu L, Zhao H, Lim JK, Taddei T, Mishra L, Pawlish K, Stroup A, Brown R, Nguyen MH, Koshiol J, Hernandez MO, Forgues M, Yang H, Lee M, Huang Y, Iwasaki M, Goto A, Suzuki S, Matsuda K, Tanikawa C, Kamatani Y, Mann D, Guarnera M, Shetty K, Thomas CE, Yuan J, Khor CC, Koh W, Risch H, Wang XW, Yu H. Genetic susceptibility to hepatocellular carcinoma in chromosome 22q13.31, findings of a genome‐wide association study. JGH Open 2021, 5: 1363-1372. PMID: 34950780, PMCID: PMC8674550, DOI: 10.1002/jgh3.12682.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseCase-control studyHepatocellular carcinomaSingle nucleotide polymorphismsChronic hepatitis C virus (HCV) infectionHepatitis C virus infectionGenetic susceptibilityC virus infectionLong-term alcohol useFatty liver diseaseUS case-control studyBody mass indexMajor risk factorGenome-wide association studiesHCV infectionCohort studyLiver diseaseCigarette smokingMass indexRisk factorsHCC casesVirus infectionGene-environment interactionsUS populationDisease riskHepatocellular Carcinoma
Jain A, Mazer B, Deng Y, Ciarleglio M, Jain D, Taddei T, Zhang X. Hepatocellular Carcinoma. American Journal Of Clinical Pathology 2021, 157: 305-313. PMID: 34542582, DOI: 10.1093/ajcp/aqab125.Peer-Reviewed Original ResearchConceptsAnaplastic tumor cellsHepatocellular carcinomaNoncirrhotic liverVascular invasionHistologic patternCirrhotic liverTumor cellsClear cell subtypePathogenesis of HCCHigh histologic gradeLarger tumor sizeHigher tumor stageHigh tumor gradeHigh rateHepatitis BHepatitis CLiver diseaseTumor sizeHistologic gradeTumor stageTumor gradePathologic differencesHCC casesRetrospective analysisPathology archives
2020
Assessing the Impact of Referral on Multidisciplinary Tumor Board Outcomes in Patients With Hepatocellular Carcinoma
Zhang Y, Weinreb J, Czeyda-Pommersheim F, Taddei T. Assessing the Impact of Referral on Multidisciplinary Tumor Board Outcomes in Patients With Hepatocellular Carcinoma. Journal Of The American College Of Radiology 2020, 17: 1636-1643. PMID: 32533924, DOI: 10.1016/j.jacr.2020.05.003.Peer-Reviewed Original ResearchConceptsMultidisciplinary liver tumor boardTertiary care institutionHepatocellular carcinomaImpact of referralHCC casesCare institutionsInitial suspicionDecreased health care costsDiagnosis of HCCIncident HCC casesUnnecessary diagnostic proceduresHealth care costsChart reviewConsensus of expertsInitial careOptimal treatmentTumor boardAmerican CollegeHCC diagnosisPatientsUnique cancerCare costsOutside institutionDiagnostic proceduresReferralFibronodular hepatocellular carcinoma—a new variant of liver cancer: clinical, pathological and radiological correlation
Tefera J, Revzin M, Chapiro J, Savic L, Mulligan D, Batra R, Taddei T, Jain D, Zhang X. Fibronodular hepatocellular carcinoma—a new variant of liver cancer: clinical, pathological and radiological correlation. Journal Of Clinical Pathology 2020, 74: 31-35. PMID: 32430483, PMCID: PMC7674234, DOI: 10.1136/jclinpath-2020-206574.Peer-Reviewed Original ResearchConceptsAdvanced Barcelona Clinic Liver Cancer stageBarcelona Clinic Liver Cancer stageScirrhous HCCMultiple rounded nodulesNon-peripheral washoutLiver Cancer stageRadiological featuresClinical featuresRadiological correlationCarcinoma variantsCancer stageHCC casesHepatocellular carcinomaLiver cancerFibrotic liverConventional HCCHCCLower ratesHigh rateRounded nodulesProgressionDistinct patternsCarcinomaSpecific variantsLesions
2018
Effect of outside referrals to a tertiary care liver tumor board on diagnostic testing and initial curative therapy.
Zhang Y, Arango J, Weinreb J, Taddei T. Effect of outside referrals to a tertiary care liver tumor board on diagnostic testing and initial curative therapy. Journal Of Clinical Oncology 2018, 36: 259-259. DOI: 10.1200/jco.2018.36.4_suppl.259.Peer-Reviewed Original ResearchMultidisciplinary tumor boardInitial curative therapyTertiary care centerLiver disease etiologyCurative therapyBCLC stageHepatocellular carcinomaCare centerTumor boardOutside institutionCases of HCCIncident HCC casesUniversity-affiliated hospitalDisease etiologyDiagnostic imaging protocolOptimal treatment planDiagnostic methodsChart reviewInitial treatmentTertiary careHCC casesOutside referralsOutside facilityTumor biopsiesAmerican College
2017
Association of change in AFP > 15 ng/ml/month with stage at diagnosis and mortality in patients with hepatocellular carcinoma (HCC).
Ilagan-Ying Y, Kaplan D, Taddei T, Njei B. Association of change in AFP > 15 ng/ml/month with stage at diagnosis and mortality in patients with hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2017, 35: 255-255. DOI: 10.1200/jco.2017.35.4_suppl.255.Peer-Reviewed Original ResearchHepatocellular carcinomaCause mortalityVeterans Administration Corporate Data WarehouseStage of HCCBCLC stage BBCLC stage DLiver disease severityAdvanced-stage cancerUseful prognostic markerAssociation of changesDate of deathLogistic regression analysisPotential hepatocellular carcinomaManual chart abstractionRegression analysisCorporate Data WarehouseChart abstractionBCLC 0Tumor burdenLiver diseaseTumor stagingUS veteransPrognostic markerHCC casesDiagnostic confirmation